Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy)
In individuals with obesity or metabolic dysfunction, this hormonal signaling system often does not function optimally, leading to persistent hunger, frequent cravings, and difficulty achieving satiety even after eating adequate meals
J.NewsomeP
Beyond weight outcomes, the Phase 2 obesity trial also reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in fasting glucose and insulin sensitivity Favourable changes in blood pressure and lipid profiles Phase 3 trials understood to form part of the TRIUMPH programme are now underway, evaluating retatrutide in broader populations including people with type 2 diabetes and cardiovascular disease
US$ 22.45
US$ 27.53
US$ 25.38
